<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423085</url>
  </required_header>
  <id_info>
    <org_study_id>CENA713D1301</org_study_id>
    <secondary_id>CENA713D1301E1</secondary_id>
    <nct_id>NCT00423085</nct_id>
    <nct_alias>NCT00531609</nct_alias>
  </id_info>
  <brief_title>Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the 5cm^2 and 10cm^2 doses of rivastigmine
      transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's
      Disease (MMSE [Mini Mental State Examination] 10-20). A 52-week extension phase evaluated the
      safety and tolerability of long-term treatment by rivastigmine transdermal patch in patients
      with probable Alzheimer's Disease (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomly assigned in a double-blind manner to one of the 3 treatment arms
      (placebo, rivastigmine 5 cm^2 and rivastigmine 10 cm^2) in a ratio of 1:1:1. During the
      Double-blind treatment phase, patients entered a 16-week Titration Period followed by an
      8-week Maintenance Period. During the open-label extension phase, all patients started
      treatment with a 2.5 cm^2 patch and the dose was increased to 10 cm^2 over a 16-week
      titration period, followed by a maintenance period of 36 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The overall clinical rating of change from baseline to week 24 measured by the 7-point CIBIC plus-J scale. The Clinician's Interview-Based Impression of Change plus Caregiver Input consists of 3 subscales: Disability Assessment of Dementia Scale, Behavioral Pathology in Alzheimer's Disease Rating Scale and Mental Function Impairment Scale, as well as the Clinician's Global Impression of Change (CGIC). Participants are scored according to the following:
Markedly improved
Moderately improved
Minimally improved
Unchanged
Minimally worse
Moderately worse
Markedly worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living (ADL). The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in ADL while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>BEHAVE-AD was used to assess patient behavior and psychiatric symptoms. It covers symptoms in seven categories: paranoid and delusional ideation, hallucinations, activity disturbances, diurnal rhythm disturbances, aggressiveness, affective disorders and anxieties, and phobias. Caregivers rate behavioral symptoms on a 0-3 scale. The total score can range from 0 to 66, with a lower score indicating better function. A negative change score indicates an improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>MENFIS was used to assess patient cognitive and psychiatric function, and evaluates core symptoms of dementia including cognitive, motivational and emotional aspects. The total score ranges from 0 to 78. The higher the score, the greater the functional deficit. A negative change score indicates an improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)</measure>
    <time_frame>Extension Phase Baseline and Week 52 of extension phase</time_frame>
    <description>The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. This outcome measured the change in MMSE from the beginning of the open-label extension phase through to Week 52 of the extension phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</measure>
    <time_frame>Extension Phase Baseline and Week 52 of extension phase</time_frame>
    <description>The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living. The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in activities of daily living while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale</measure>
    <time_frame>Extension Phase Baseline and Week 52 of extension phase</time_frame>
    <description>The Modified Crichton Scale includes a total of seven items evaluated in eight grades that assess basic activities of daily living, communication functions, psychiatric symptoms and quality of life; the total score can range from 0 to 56, with a lower score indicating better function. A negative change score indicates an improvement from baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">859</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivastigmine 5 cm^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivastigmine 10 cm^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine transdermal patch</intervention_name>
    <description>Rivastigmine transdermal patch was provided in the following sizes and doses:
2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.</description>
    <arm_group_label>rivastigmine 5 cm^2</arm_group_label>
    <arm_group_label>Rivastigmine 10 cm^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria

          -  A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria

          -  An MMSE score of &gt; or = 10 and &lt; or = 20

        Exclusion Criteria:

          -  A current DSM-IV diagnosis of major depression

          -  Taken rivastigmine in the past

          -  A score of &gt; 5 on the Modified Hachinski Ischemic Scale (MHIS) Other protocol-defined
             inclusion/exclusion criteria may apply

        Other protocol-defined inclusion/exclusion criteria may apply

        Extension Phase Eligibility Criteria

        Inclusion Criteria:

          -  Patients who have completed the Double-blind Treatment Phase on study medication

        Exclusion Criteria

          -  Patients who have any important protocol deviations until the completion of the
             Double-blind Treatment Phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hokkaido region</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <results_first_submitted>April 27, 2011</results_first_submitted>
  <results_first_submitted_qc>April 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2011</results_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rivastigmine，Alzheimer's Disease, transdermal patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomly assigned in a double-blind manner to one of the 3 treatment arms (placebo, rivastigmine 5 cm^2 and rivastigmine 10 cm^2) in a ratio of 1:1:1. Following the 24-week double-blind treatment phase, participants could enroll in the open-label extension phase, where all participants were titrated up to the 10 cm^2 patch dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
        </group>
        <group group_id="P2">
          <title>Rivastigmine 5 cm^2</title>
          <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
        </group>
        <group group_id="P3">
          <title>Rivastigmine 10 cm^2</title>
          <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
        </group>
        <group group_id="P4">
          <title>Open-label Extension</title>
          <description>All participants started treatment with daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period). A predetermined &quot;allowed adjustment&quot; scheme was followed in patients who required dose adjustment due to low tolerability.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>24-Week Double-Blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="287"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="228"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>52-Week Open-Label Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="637">Patients who completed the 24-wk treatment phase were eligible to enroll in the open-label extension</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="163"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="97"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
        </group>
        <group group_id="B2">
          <title>Rivastigmine 5 cm^2</title>
          <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
        </group>
        <group group_id="B3">
          <title>Rivastigmine 10 cm^2</title>
          <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="286"/>
            <count group_id="B2" value="282"/>
            <count group_id="B3" value="287"/>
            <count group_id="B4" value="855"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Demographic data for the double-blind treatment phase is provided for the safety population. This population consists of all randomized patients who received at least one dose of study medication and had at least one safety assessment after baseline.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="7.36"/>
                    <measurement group_id="B2" value="74.3" spread="7.46"/>
                    <measurement group_id="B3" value="75.1" spread="6.85"/>
                    <measurement group_id="B4" value="74.6" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</title>
        <description>The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The Intent-to-treat population: This population includes all randomized patients who received at least one dose of study drug and had at least a baseline and any post-baseline assessment on treatment (i.e. not more than 2 days after the last known date of study drug) for one of the primary efficacy variables. LOCF was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 5 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
          <group group_id="O3">
            <title>Rivastigmine 10 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</title>
          <description>The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.</description>
          <population>The Intent-to-treat population: This population includes all randomized patients who received at least one dose of study drug and had at least a baseline and any post-baseline assessment on treatment (i.e. not more than 2 days after the last known date of study drug) for one of the primary efficacy variables. LOCF was utilized.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="9.46"/>
                    <measurement group_id="O2" value="25.2" spread="9.62"/>
                    <measurement group_id="O3" value="25.0" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="11.49"/>
                    <measurement group_id="O2" value="25.7" spread="11.70"/>
                    <measurement group_id="O3" value="25.1" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="5.07"/>
                    <measurement group_id="O2" value="0.5" spread="4.96"/>
                    <measurement group_id="O3" value="0.1" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</title>
        <description>The overall clinical rating of change from baseline to week 24 measured by the 7-point CIBIC plus-J scale. The Clinician's Interview-Based Impression of Change plus Caregiver Input consists of 3 subscales: Disability Assessment of Dementia Scale, Behavioral Pathology in Alzheimer's Disease Rating Scale and Mental Function Impairment Scale, as well as the Clinician's Global Impression of Change (CGIC). Participants are scored according to the following:
Markedly improved
Moderately improved
Minimally improved
Unchanged
Minimally worse
Moderately worse
Markedly worse</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-treat population utilizing LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 5 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
          <group group_id="O3">
            <title>Rivastigmine 10 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</title>
          <description>The overall clinical rating of change from baseline to week 24 measured by the 7-point CIBIC plus-J scale. The Clinician's Interview-Based Impression of Change plus Caregiver Input consists of 3 subscales: Disability Assessment of Dementia Scale, Behavioral Pathology in Alzheimer's Disease Rating Scale and Mental Function Impairment Scale, as well as the Clinician's Global Impression of Change (CGIC). Participants are scored according to the following:
Markedly improved
Moderately improved
Minimally improved
Unchanged
Minimally worse
Moderately worse
Markedly worse</description>
          <population>Intent-to-treat population utilizing LOCF.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Markedly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Markedly worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</title>
        <description>The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living (ADL). The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in ADL while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 5 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
          <group group_id="O3">
            <title>Rivastigmine 10 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</title>
          <description>The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living (ADL). The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in ADL while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.</description>
          <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.70" spread="19.902"/>
                    <measurement group_id="O2" value="64.19" spread="20.571"/>
                    <measurement group_id="O3" value="64.15" spread="21.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.54" spread="22.395"/>
                    <measurement group_id="O2" value="61.19" spread="22.415"/>
                    <measurement group_id="O3" value="62.27" spread="23.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="12.443"/>
                    <measurement group_id="O2" value="-2.99" spread="10.259"/>
                    <measurement group_id="O3" value="-1.88" spread="10.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</title>
        <description>BEHAVE-AD was used to assess patient behavior and psychiatric symptoms. It covers symptoms in seven categories: paranoid and delusional ideation, hallucinations, activity disturbances, diurnal rhythm disturbances, aggressiveness, affective disorders and anxieties, and phobias. Caregivers rate behavioral symptoms on a 0–3 scale. The total score can range from 0 to 66, with a lower score indicating better function. A negative change score indicates an improvement from baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 5 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
          <group group_id="O3">
            <title>Rivastigmine 10 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</title>
          <description>BEHAVE-AD was used to assess patient behavior and psychiatric symptoms. It covers symptoms in seven categories: paranoid and delusional ideation, hallucinations, activity disturbances, diurnal rhythm disturbances, aggressiveness, affective disorders and anxieties, and phobias. Caregivers rate behavioral symptoms on a 0–3 scale. The total score can range from 0 to 66, with a lower score indicating better function. A negative change score indicates an improvement from baseline.</description>
          <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.50"/>
                    <measurement group_id="O2" value="4.7" spread="4.96"/>
                    <measurement group_id="O3" value="5.4" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.41"/>
                    <measurement group_id="O2" value="4.6" spread="5.03"/>
                    <measurement group_id="O3" value="5.1" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.76"/>
                    <measurement group_id="O2" value="-0.1" spread="4.17"/>
                    <measurement group_id="O3" value="-0.3" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)</title>
        <description>MENFIS was used to assess patient cognitive and psychiatric function, and evaluates core symptoms of dementia including cognitive, motivational and emotional aspects. The total score ranges from 0 to 78. The higher the score, the greater the functional deficit. A negative change score indicates an improvement from baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 5 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
          <group group_id="O3">
            <title>Rivastigmine 10 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)</title>
          <description>MENFIS was used to assess patient cognitive and psychiatric function, and evaluates core symptoms of dementia including cognitive, motivational and emotional aspects. The total score ranges from 0 to 78. The higher the score, the greater the functional deficit. A negative change score indicates an improvement from baseline.</description>
          <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="11.13"/>
                    <measurement group_id="O2" value="24.3" spread="11.72"/>
                    <measurement group_id="O3" value="24.6" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="12.68"/>
                    <measurement group_id="O2" value="26.5" spread="13.43"/>
                    <measurement group_id="O3" value="26.2" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="6.18"/>
                    <measurement group_id="O2" value="2.2" spread="5.86"/>
                    <measurement group_id="O3" value="1.6" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mini-Mental State Examination (MMSE)</title>
        <description>The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>Rivastigmine 5 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and then daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
          <group group_id="O3">
            <title>Rivastigmine 10 cm^2</title>
            <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini-Mental State Examination (MMSE)</title>
          <description>The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.</description>
          <population>Intent-to-treat population. Only patients with a valid baseline and post-baseline score were included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="2.87"/>
                    <measurement group_id="O2" value="16.9" spread="2.88"/>
                    <measurement group_id="O3" value="16.4" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="4.21"/>
                    <measurement group_id="O2" value="16.6" spread="4.62"/>
                    <measurement group_id="O3" value="16.4" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.82"/>
                    <measurement group_id="O2" value="-0.3" spread="3.05"/>
                    <measurement group_id="O3" value="0.0" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)</title>
        <description>The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. This outcome measured the change in MMSE from the beginning of the open-label extension phase through to Week 52 of the extension phase.</description>
        <time_frame>Extension Phase Baseline and Week 52 of extension phase</time_frame>
        <population>Intent-to-treat population utilizing last observation carried forward. This population includes all patients who received at least one dose of open-label study medication and had at least one efficacy assessment on treatment in the open-label extension Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Extension Arm</title>
            <description>All participants started treatment with a daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and then 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period) for a total of 52 weeks. A predetermined &quot;allowed adjustment&quot; scheme was followed in participants who required dose adjustment due to low tolerability.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)</title>
          <description>The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. This outcome measured the change in MMSE from the beginning of the open-label extension phase through to Week 52 of the extension phase.</description>
          <population>Intent-to-treat population utilizing last observation carried forward. This population includes all patients who received at least one dose of open-label study medication and had at least one efficacy assessment on treatment in the open-label extension Phase.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Extension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</title>
        <description>The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living. The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in activities of daily living while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.</description>
        <time_frame>Extension Phase Baseline and Week 52 of extension phase</time_frame>
        <population>Intent-to-treat population utilizing last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Extension Arm</title>
            <description>All participants started treatment with a daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and then 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period) for a total of 52 weeks. A predetermined &quot;allowed adjustment&quot; scheme was followed in participants who required dose adjustment due to low tolerability.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)</title>
          <description>The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living. The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in activities of daily living while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.</description>
          <population>Intent-to-treat population utilizing last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="567"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.99" spread="22.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Extension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.95" spread="25.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.04" spread="14.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale</title>
        <description>The Modified Crichton Scale includes a total of seven items evaluated in eight grades that assess basic activities of daily living, communication functions, psychiatric symptoms and quality of life; the total score can range from 0 to 56, with a lower score indicating better function. A negative change score indicates an improvement from baseline.</description>
        <time_frame>Extension Phase Baseline and Week 52 of extension phase</time_frame>
        <population>Intent-to-treat population utilizing last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Open-label Extension Arm</title>
            <description>All participants started treatment with a daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and then 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period) for a total of 52 weeks. A predetermined &quot;allowed adjustment&quot; scheme was followed in participants who required dose adjustment due to low tolerability.</description>
          </group>
        </group_list>
        <measure>
          <title>Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale</title>
          <description>The Modified Crichton Scale includes a total of seven items evaluated in eight grades that assess basic activities of daily living, communication functions, psychiatric symptoms and quality of life; the total score can range from 0 to 56, with a lower score indicating better function. A negative change score indicates an improvement from baseline.</description>
          <population>Intent-to-treat population utilizing last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extension Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Extension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="11.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the 24-week double-blind treatment phase and during the 52-week open-label extension phase.</time_frame>
      <desc>Data presented in the Placebo, Rivastigmine 5 cm^2 and Rivastigmine 10 cm^2 columns represent AEs collected during the 24-week double blind treatment phase of the study. Data presented in the Open-Label Extension column are AEs collected during the 52-week open-label extension phase of the study, after completion of the double-blind phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (24 Weeks)</title>
          <description>Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.</description>
        </group>
        <group group_id="E2">
          <title>Rivastigmine 5 cm^2 (24 Weeks)</title>
          <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
        </group>
        <group group_id="E3">
          <title>Rivastigmine 10 cm^2 (24 Weeks)</title>
          <description>During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.</description>
        </group>
        <group group_id="E4">
          <title>Open-Label Extension (52 Weeks)</title>
          <description>All participants started treatment with daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period). A predetermined &quot;allowed adjustment&quot; scheme was followed in patients who required dose adjustment due to low tolerability.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Vertebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Fracture delayed union</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Inflammatory carcinoma of the breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Behavioural and psychiatric symptoms of dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="214" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="491" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="220" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="637"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="201" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="287"/>
                <counts group_id="E4" subjects_affected="162" subjects_at_risk="637"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

